Viruses (Mar 2023)

Oncolytic Efficacy of a Recombinant Vaccinia Virus Strain Expressing Bacterial Flagellin in Solid Tumor Models

  • Yasmin Shakiba,
  • Pavel O. Vorobyev,
  • Victor A. Naumenko,
  • Dmitry V. Kochetkov,
  • Ksenia V. Zajtseva,
  • Marat P. Valikhov,
  • Gaukhar M. Yusubalieva,
  • Yana D. Gumennaya,
  • Egor A. Emelyanov,
  • Alevtina S. Semkina,
  • Vladimir P. Baklaushev,
  • Peter M. Chumakov,
  • Anastasia V. Lipatova

DOI
https://doi.org/10.3390/v15040828
Journal volume & issue
Vol. 15, no. 4
p. 828

Abstract

Read online

Oncolytic viral therapy is a promising novel approach to cancer treatment. Oncolytic viruses cause tumor regression through direct cytolysis on the one hand and recruiting and activating immune cells on the other. In this study, to enhance the antitumor efficacy of the thymidine kinase-deficient vaccinia virus (VV, Lister strain), recombinant variants encoding bacterial flagellin (subunit B) of Vibrio vulnificus (LIVP-FlaB-RFP), firefly luciferase (LIVP-Fluc-RFP) or red fluorescent protein (LIVP-RFP) were developed. The LIVP-FLuc-RFP strain demonstrated exceptional onco-specificity in tumor-bearing mice, detected by the in vivo imaging system (IVIS). The antitumor efficacy of these variants was explored in syngeneic murine tumor models (B16 melanoma, CT26 colon cancer and 4T1 breast cancer). After intravenous treatment with LIVP-FlaB-RFP or LIVP-RFP, all mice tumor models exhibited tumor regression, with a prolonged survival rate in comparison with the control mice. However, superior oncolytic activity was observed in the B16 melanoma models treated with LIVP-FlaB-RFP. Tumor-infiltrated lymphocytes and the cytokine analysis of the serum and tumor samples from the melanoma-xenografted mice treated with these virus variants demonstrated activation of the host’s immune response. Thus, the expression of bacterial flagellin by VV can enhance its oncolytic efficacy against immunosuppressive solid tumors.

Keywords